BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at ...
Medicare’s new GLP-1 bridge program will provide eligible Part D prescription plan enrollees inexpensive monthly copays for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results